A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
- Registration Number
- NCT00679731
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Brief Summary
This study is being conducted to compare the efficacy of ABT-874 versus Methotrexate in subjects with moderate to severe plaque psoriasis.
- Detailed Description
This study is only being conducted in the EU and Canada
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 317
- Diagnosis of Psoriasis for 6 MO.. BSA 10%, PASI 12 or above, PGA 3 or above
- Previous exposure to anti-IL 12
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description A ABT-874 ABT-874 B Methotrexate Methotrexate
- Primary Outcome Measures
Name Time Method Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 24 Week 24 The proportion of subjects who achieve a PGA score of 0 or 1 at Week 24 Week 24 Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 52 Week 52 The proportion of subjects who achieve a PGA score of 0 or 1 at Week 52 Week 52
- Secondary Outcome Measures
Name Time Method Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 24 Week 24 Changes from Baseline in the DLQI total score at Week 24 Week 24 Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 52 Week 52 Changes from Baseline in the DLQI total score at Week 52 Week 52
Trial Locations
- Locations (43)
Site Reference ID/Investigator# 12763
🇦🇹Vienna, Austria
Site Reference ID/Investigator# 13104
🇨🇦Barrie, Canada
Site Reference ID/Investigator# 8185
🇸🇪Stockholm, Sweden
Site Reference ID/Investigator# 11661
🇫🇷Creteil, France
Site Reference ID/Investigator# 8025
🇩🇪Berlin, Germany
Site Reference ID/Investigator# 8032
🇩🇪Hamburg, Germany
Site Reference ID/Investigator# 8027
🇩🇪Kiel, Germany
Site Reference ID/Investigator# 11504
🇫🇷Nice, France
Site Reference ID/Investigator# 12401
🇬🇧Aberdeen, United Kingdom
Site Reference ID/Investigator# 8362
🇪🇸Valencia, Spain
Site Reference ID/Investigator# 13163
🇪🇸Seville, Spain
Site Reference ID/Investigator# 8551
🇮🇹Rome, Italy
Site Reference ID/Investigator# 13223
🇨🇦Quebec City, Canada
Site Reference ID/Investigator# 8030
🇫🇮Helsinki, Finland
Site Reference ID/Investigator# 13461
🇬🇷Thessaloniki, Greece
Site Reference ID/Investigator# 8034
🇬🇧Manchester, United Kingdom
Site Reference ID/Investigator# 13221
🇨🇦Waterloo, Canada
Site Reference ID/Investigator# 8026
🇫🇮Turku, Finland
Site Reference ID/Investigator# 9583
🇮🇹Modena, Italy
Site Reference ID/Investigator# 10963
🇫🇷Toulouse Cedex 9, France
Site Reference ID/Investigator# 8019
🇩🇪Muenster, Germany
Site Reference ID/Investigator# 11864
🇨🇦Hamilton, Canada
Site Reference ID/Investigator# 12381
🇮🇹Milan, Italy
Site Reference ID/Investigator# 10702
🇪🇸Madrid, Spain
Site Reference ID/Investigator# 8035
🇩🇪Munich, Germany
Site Reference ID/Investigator# 13481
🇪🇸Barcelona, Spain
Site Reference ID/Investigator# 11381
🇩🇰Aarhus, Denmark
Site Reference ID/Investigator# 11841
🇩🇰Copenhagen NV, Denmark
Site Reference ID/Investigator# 11161
🇫🇷Paris, France
Site Reference ID/Investigator# 8023
🇩🇪Tuebingen, Germany
Site Reference ID/Investigator# 13161
🇨🇦Halifax, Canada
Site Reference ID/Investigator# 8024
🇩🇪Frankfurt am Main, Germany
Site Reference ID/Investigator# 9904
🇦🇹Graz, Austria
Site Reference ID/Investigator# 11001
🇦🇹Vienna, Austria
Site Reference ID/Investigator# 8363
🇳🇱Nijmegen, Netherlands
Site Reference ID/Investigator# 10203
🇨ðŸ‡Geneva 14, Switzerland
Site Reference ID/Investigator# 8022
🇧🇪Brussels, Belgium
Site Reference ID/Investigator# 13422
🇬🇷Athens, Greece
Site Reference ID/Investigator# 13462
🇬🇷Athens, Greece
Site Reference ID/Investigator# 8033
🇫🇮Kuopio, Finland
Site Reference ID/Investigator# 8021
🇫🇮Lahti, Finland
Site Reference ID/Investigator# 11701
🇳🇱Amsterdam, Netherlands
Site Reference ID/Investigator# 8020
🇨ðŸ‡Zurich, Switzerland